Oppenheimer analyst Hartaj Singh lowered the firm’s price target on Spruce Biosciences to $7 from $8 and keeps an Outperform rating on the shares after the company reported Q2 results. With early validation in PCOS and upcoming late-stage readouts in CAH, the firm updates its model and valuation, and remains bullish.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SPRB: